Why Early Detection of Diabetic Peripheral Neuropathy Matters
Diabetic peripheral neuropathy (DPN) is one of the most common and consequential complications of diabetes, affecting up to half of all people living with type 1 or type 2 diabetes over the course of their disease. It is a leading cause of disabling neuropathic pain and lower-limb amputation. The stakes are high: amputation profoundly reduces quality of life and is associated with strikingly poor survival, with average life expectancy of roughly two years following the procedure. Yet DPN is frequently identified late, after irreversible nerve damage has already taken place. Understanding how the condition develops, how it can be detected early, and what reduces its progression is central to protecting the feet and the broader health of people with diabetes.
How Nerve Damage Develops
DPN typically follows a distal-to-proximal pattern, meaning the longest nerves—those reaching the toes and feet—are affected first, which is why symptoms so often begin in the feet before the hands. The damage reflects a progressive loss of peripheral nerve function. Research increasingly points to a unifying mechanism of bioenergetic failure within peripheral nerves, whose unique length and metabolic demands make them especially vulnerable to the metabolic stress of diabetes.
Risk factors differ between diabetes types. In type 1 diabetes, sustained high blood glucose (hyperglycemia) is a dominant driver. In type 2 diabetes, the picture is more complex: the metabolic syndrome—the cluster of obesity, high blood pressure, abnormal lipids, and insulin resistance—is a major contributor, often acting alongside elevated glucose. This distinction has important implications for prevention.
Screening and Early Diagnosis
Because nerve injury can advance silently, structured screening is essential. Many patients lose protective sensation without realizing it, leaving them unaware that a minor blister or pressure point could progress to an ulcer. Simple, validated bedside tests—such as the 10-gram monofilament to assess protective sensation, tuning-fork testing for vibration, and assessment of ankle reflexes and pinprick—remain the foundation of clinical screening and can be performed during a routine foot examination.
A persistent challenge is that these traditional methods often detect neuropathy only once it is well established. To close that gap, researchers have developed innovative point-of-care devices designed to identify nerve dysfunction earlier, when the condition may be more responsive to intervention. The goal of this shift is to move screening upstream—catching subtle small-fiber and large-fiber changes before they translate into numbness, deformity, or wounds.
Prevention and Management
The evidence on blood glucose control illustrates why a tailored approach matters. Intensive glycemic control clearly prevents the development of neuropathy in type 1 diabetes. In type 2 diabetes, however, glucose lowering alone has shown only modest or even negligible benefit for neuropathy, likely because coexisting cardiometabolic conditions also drive nerve injury. For this reason, a multifactorial strategy—addressing glucose, blood pressure, lipids, weight, and lifestyle together—offers the best prospect for slowing DPN. Modern type 2 diabetes care has expanded to include agents such as SGLT2 inhibitors and GLP-1 receptor agonists that improve glycemic and cardiovascular risk profiles, complementing physical activity and dietary change.
Once neuropathy is present, management focuses on three priorities: optimizing individualized cardiometabolic targets, preventing foot complications through multidisciplinary care, and treating neuropathic pain when it occurs. Painful DPN can be difficult to control, but evidence suggests that a mechanism-based approach, matching treatment to a patient’s specific pain phenotype, may improve outcomes compared with a one-size-fits-all strategy. Protective foot care—regular inspection, appropriate footwear, and prompt attention to any skin breakdown—remains a cornerstone of preventing the ulcers and amputations that neuropathy makes possible.
Key Takeaways
Diabetic peripheral neuropathy is common, often silent, and potentially devastating, but it is not inevitable in its worst forms. Early and regular screening, including simple sensory testing and emerging point-of-care tools, allows the condition to be recognized before protective sensation is lost. Prevention depends on tight glycemic control in type 1 diabetes and a broader, multifactorial cardiometabolic strategy in type 2 diabetes. When neuropathy develops, individualized risk-factor management, vigilant foot protection, and mechanism-informed pain treatment together offer the best chance of preserving mobility, comfort, and limb health.
References
Selvarajah D, Kar D, Khunti K, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. The Lancet Diabetes & Endocrinology. 2019;7(12):938–948.
Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nature Reviews Endocrinology. 2021;17(7):400–420.
Elafros MA, Andersen H, Bennett DL, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. The Lancet Neurology. 2022;21(10):922–936.
Młynarska E, Czarnik W, Dzieża N, et al. Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. International Journal of Molecular Sciences. 2025;26(3):1094.
Comments
